| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/05/2009 | CA2698552A1 Transition metal complexes of corroles for preventing cardiovascular diseases or disorders |
| 03/05/2009 | CA2698457A1 Methods for improving healing of an oral lesion using a glycerophosphate salt |
| 03/05/2009 | CA2698135A1 Osmolytes for treating allergic or viral respiratory diseases |
| 03/05/2009 | CA2698115A1 Treatment of autoimmune disease |
| 03/05/2009 | CA2698094A1 Compounds for inhibiting wip1, prodrugs and compositions thereof, and related methods |
| 03/05/2009 | CA2698075A1 Antiviral drugs for treatment of arenavirus infection |
| 03/05/2009 | CA2698071A1 Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| 03/05/2009 | CA2698018A1 Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof |
| 03/05/2009 | CA2697990A1 Medication combinations for the treatment of alcoholism and drug addiction |
| 03/05/2009 | CA2697971A1 Quinolin-4-one and 4-oxodihydrocinnoline derivatives as inhibitors of poly(adp-ribose)polymerase (parp) |
| 03/05/2009 | CA2697950A1 Polymorphs of prostaglandin agonists and methods for making the same |
| 03/05/2009 | CA2697943A1 Local topical administration formulations containing fipronil |
| 03/05/2009 | CA2697900A1 Inhibitor of ischemic disorders |
| 03/05/2009 | CA2697895A1 Agent for promoting corneal endothelial cell adhesion |
| 03/05/2009 | CA2697862A1 Supramacromolecular polymer complexes providing controlled nitric oxide release for healing wounds |
| 03/05/2009 | CA2697837A1 Synthesis of oseltamivir containing phosphonate congeners with anti-influenza activity |
| 03/05/2009 | CA2697827A1 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases |
| 03/05/2009 | CA2697825A1 Non-aqueous pharmaceutical compositions |
| 03/05/2009 | CA2697795A1 Inhibitors of protein tyrosine kinase activity |
| 03/05/2009 | CA2697739A1 Compositions and methods employing nmda antagonists for achieving an anesthetic-sparing effect |
| 03/05/2009 | CA2697724A1 Method for splitting omeprazole salts |
| 03/05/2009 | CA2697709A1 Use of compounds derived from cycloheximide for treating or preventing, in particular, ischaemias and cardiopathies |
| 03/05/2009 | CA2697688A1 Catecholamine derivatives and prodrugs thereof |
| 03/05/2009 | CA2697681A1 Selective cytopheresis devices and related methods thereof |
| 03/05/2009 | CA2697670A1 Method for production of carotenoid |
| 03/05/2009 | CA2697663A1 Substituted pyrazole derivative |
| 03/05/2009 | CA2697517A1 Cancer-related genes, cdca5, epha7, stk31 and wdhd1 |
| 03/05/2009 | CA2697513A1 Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis |
| 03/05/2009 | CA2697512A1 Pkib and naaladl2 for target genes of prostate cancer therapy and diagnosis |
| 03/05/2009 | CA2697501A1 Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent |
| 03/05/2009 | CA2697382A1 4-(4-pyridinyl)-benzamides and their use as rock activity modulators |
| 03/05/2009 | CA2697368A1 Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds |
| 03/05/2009 | CA2697363A1 Modulation of synaptogenesis |
| 03/05/2009 | CA2697167A1 Benzimidazole derivatives used as fxr agonists |
| 03/05/2009 | CA2697070A1 Methods of inhibiting tumor growth using beta 5 integrin antagonists |
| 03/05/2009 | CA2696922A1 Carbamate stereoisomer |
| 03/05/2009 | CA2696898A1 Process for the preparation of pyrido [2,1-a] isoquinoline derivatives and polymorphic forms thereof |
| 03/05/2009 | CA2696799A1 Piperidine derivative |
| 03/05/2009 | CA2696767A1 Heterocyclic amides useful for the treatment of cancer and psoriasis |
| 03/05/2009 | CA2696622A1 Compositions for the treatment of neoplastic diseases |
| 03/05/2009 | CA2696609A1 Therapeutic isoxazole compounds |
| 03/05/2009 | CA2696030A1 Use of gestagens in combination with (6s)-5-methyltetrahydrofolate for therapy of endometriosis with simultaneous reduction of therapy side effects and reduction of the risk of congenital abnormalities at the onset of a pregnancy |
| 03/05/2009 | CA2696009A1 Antiviral composition comprising a sulfated polysaccharide |
| 03/05/2009 | CA2695822A1 A combination treatment |
| 03/05/2009 | CA2695781A1 Compounds for the treatment of hepatitis c |
| 03/05/2009 | CA2695755A1 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists |
| 03/05/2009 | CA2695503A1 Tsh receptor antagonizing tetrahydroquinoline compounds |
| 03/05/2009 | CA2694911A1 Substituted piperazinyl pyrazines and pyridines as 5-ht7 receptor antagonists |
| 03/05/2009 | CA2691961A1 Catecholamine derivatives and prodrugs thereof |
| 03/05/2009 | CA2691448A1 Triazolopyridine compounds and their use as ask inhibitors |
| 03/05/2009 | CA2679244A1 Nucleic acid compounds for inhibiting myc gene expression and uses thereof |
| 03/04/2009 | EP2031061A2 siDNA against influenza virus |
| 03/04/2009 | EP2031060A1 siDNA against influenza virus |
| 03/04/2009 | EP2031059A1 siDNA against hepatites C virus (HCV) |
| 03/04/2009 | EP2031057A1 SENSE OLIGONUCLEOTIDE CAPABLE OF CONTROLLING THE EXPRESSION OF iNOS AND COMPOSITION COMPRISING THE SAME |
| 03/04/2009 | EP2031056A1 Method for controlling the amount of gene product, and agent for controlling the amount of gene product |
| 03/04/2009 | EP2030981A1 Compounds for proteasome enzyme inhibition |
| 03/04/2009 | EP2030979A1 Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi |
| 03/04/2009 | EP2030978A1 Phosphine transition metal complex, method for producing the same and antitumor agent |
| 03/04/2009 | EP2030974A1 Heterocyclic non-nucleoside compounds, their peparation, pharmaceutical composition and their use as antiviral agents |
| 03/04/2009 | EP2030970A1 Allosteric modulators of metabotropic glutamate receptors |
| 03/04/2009 | EP2030969A1 Spirocyclic 3-phenyl-3-substituted 4-ketolactams and 4-ketolactones |
| 03/04/2009 | EP2030968A2 Sulfur-containing compound, method of preparation and pharmaceutical uses thereof |
| 03/04/2009 | EP2030624A1 Antioxidant and paramagnetic heparin-nitroxide derivatives |
| 03/04/2009 | EP2030623A1 Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria |
| 03/04/2009 | EP2030622A1 Dosage regimen for the treatment of a traumatic brain injury with progesterone |
| 03/04/2009 | EP2030621A1 Novel substituted pyrimidines as cysteine protease inhibitors |
| 03/04/2009 | EP2030620A1 (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents |
| 03/04/2009 | EP2030619A1 Use of dopamine stabilizers |
| 03/04/2009 | EP2030618A2 Combinations comprising epothilones and anti-metabolites |
| 03/04/2009 | EP2030617A1 Use of tranilast and derivatives thereof for the therapy of neurological conditions |
| 03/04/2009 | EP2030616A1 Short-chain fatty acid derivatives for treating pruritus |
| 03/04/2009 | EP2030615A2 Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases |
| 03/04/2009 | EP2030614A1 Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin |
| 03/04/2009 | EP2030613A1 Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics |
| 03/04/2009 | EP2030612A1 Pharmaceutical composition for treating burns (variants) and a method for the production thereof (variants) |
| 03/04/2009 | EP2030610A1 Non-aqueous pharmaceutical compositions |
| 03/04/2009 | EP2030509A1 Proanthocyanidin-containing tea beverage |
| 03/04/2009 | EP2030020A2 Aptamers directed to recombinant muc1 |
| 03/04/2009 | EP2029746A2 Compositions and methods for sirna inhibition of angiogenesis |
| 03/04/2009 | EP2029743A1 Methods of diagnosing and treating complications of pregnancy |
| 03/04/2009 | EP2029612A1 Substituted 1-methyl-1h-quinolin-2-ones and 1-methyl-1h-1,5-naphthyridin-2-ones as antibacterials |
| 03/04/2009 | EP2029611A2 17-desmethylrapamycin and analogues thereof, methods for their production and their use as immunosupressants, anticancer agents, antifungal agents etc. |
| 03/04/2009 | EP2029610A2 Novel mch receptor antagonists |
| 03/04/2009 | EP2029609A2 Novel mch receptor antagonists |
| 03/04/2009 | EP2029608A1 Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use |
| 03/04/2009 | EP2029607A1 Novel 8,10-diaza-bicycloý4.3.1¨decane derivatives and their medical use |
| 03/04/2009 | EP2029606A2 Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
| 03/04/2009 | EP2029605A1 Imidazopyrazines as protein kinase inhibitors |
| 03/04/2009 | EP2029604A2 Aldosterone synthase and/or 11beta-hydroxylase inhibitors |
| 03/04/2009 | EP2029603A1 Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor |
| 03/04/2009 | EP2029602A2 Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases |
| 03/04/2009 | EP2029601A1 Pyridopyrimidinone derivatives |
| 03/04/2009 | EP2029600A1 Substituted pteridines substituted with a four-membered heterocycle |
| 03/04/2009 | EP2029598A1 2-thioxanthine derivatives acting as mpo-inhibitors |
| 03/04/2009 | EP2029597A2 Purine analogs |
| 03/04/2009 | EP2029596A2 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzothiazepines, the preparation and use thereof, and compositions containing the same |
| 03/04/2009 | EP2029595A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use |
| 03/04/2009 | EP2029594A1 Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use |
| 03/04/2009 | EP2029593A1 Indole derivatives |